Wealthfront Advisers LLC Has $15.04 Million Stake in Bristol Myers Squibb Company $BMY

Wealthfront Advisers LLC lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 4.9% during the third quarter, Holdings Channel.com reports. The firm owned 333,414 shares of the biopharmaceutical company’s stock after selling 17,324 shares during the period. Wealthfront Advisers LLC’s holdings in Bristol Myers Squibb were worth $15,037,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Norges Bank bought a new position in shares of Bristol Myers Squibb in the second quarter valued at about $1,554,154,000. Charles Schwab Investment Management Inc. increased its position in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after acquiring an additional 9,171,098 shares during the last quarter. Man Group plc lifted its position in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Bristol Myers Squibb by 142.8% during the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after purchasing an additional 4,961,869 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 0.1%

Shares of Bristol Myers Squibb stock opened at $60.82 on Wednesday. The business has a fifty day simple moving average of $54.82 and a 200 day simple moving average of $49.20. The stock has a market cap of $123.81 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BMY. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Finally, HSBC restated a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.